Prediction of Acute Mountain Sickness using a Blood-Based Test

Abstract

In the last year we have completed analysis of Phase II of the project. In Phase I we showed that an RNA-based gene signature from a sample taken at sea level could be used to successfully predict in 9 out of 10 individuals who went onto develop acute mountain sickness or who was AMS resistant. In Phase II, results suggest a completely independent sample was equally effective in predicting AMS susceptibility and resistance. These results were presented to the scientific leadership at Fort Detrick last spring. Under the advisement of that review process we have taken an expanded view of the data we are using for predicting AMS. Specifically, in addition to the data collected in this project for Phase I and Phase II, we will add several data sets to the overall analysis. New dataset 1 is analyses of an additional 70 samples from Phase I.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jan 01, 2016
Accession Number
AD1016208

Entities

People

  • Robert Roach

Organizations

  • University of Colorado Denver

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Algorithms
  • Altitude
  • Biological Factors
  • Biomedical Information Systems
  • Biomedical Research
  • Colorado
  • Computational Biology
  • Data Sets
  • Department Of Defense
  • Dna Microarrays
  • Gene Expression
  • Hematologic Tests
  • High Altitude
  • Microarray Analysis
  • Mountains
  • Sea Level

Readers

  • Brain and Cognitive Science; Experimental Psychology; Cognitive Neuroscience
  • Clinical Trial Research.
  • Oncology and Biomarker-Based Cancer Detection.